Precision Biosciences (DTIL) Free Cash Flow (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Free Cash Flow data on file, last reported at -$12.0 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 37.46% year-over-year to -$12.0 million in Q1 2026; TTM through Mar 2026 was -$58.8 million, a 0.04% change from a year earlier, with the FY2025 full-year figure at -$65.9 million, down 12.32% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$12.0 million, down from -$11.3 million in the prior quarter.
• Over the last five years, Free Cash Flow for DTIL reached as high as $28.1 million in Q3 2022 and fell as low as -$32.0 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$16.0 million across 5 years, with a median of -$19.1 million in 2024.
• Across the five-year window, Free Cash Flow surged 214.04% in 2022 and tumbled 183.57% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$22.5 million in 2022, then jumped by 62.64% to -$8.4 million in 2023, then sank by 123.65% to -$18.8 million in 2024, then surged by 39.99% to -$11.3 million in 2025, then retreated by 6.09% to -$12.0 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$12.0 million in Q1 2026, -$11.3 million in Q4 2025, and -$15.3 million in Q3 2025.